المؤلفون: van Gelder, M., van Oers, M. H., Alemayehu, W. G., Abrahamse-Testroote, M. C. J., Cornelissen, J. J., Chamuleau, M. E., Zachee, P., Hoogendoorn, M., Nijland, M., Petersen, E. J., Beeker, A., Timmers, G-J, Verdonck, L., Westerman, M., de Weerdt, O., Kater, A. P.

المصدر: van Gelder , M , van Oers , M H , Alemayehu , W G , Abrahamse-Testroote , M C J , Cornelissen , J J , Chamuleau , M E , Zachee , P , Hoogendoorn , M , Nijland , M , Petersen , E J , Beeker , A , Timmers , G-J , Verdonck , L , Westerman , M , de Weerdt , O & Kater , A P 2016 , ' Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study ' ....

الوصف: Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen

الإتاحة: https://doi.org/10.1038/bmt.2016.9Test
https://cris.maastrichtuniversity.nl/en/publications/ec477134-f941-49b4-afe6-45a0a7705940Test

المؤلفون: Ezekowitz J. A., O'Connor C. M., Troughton R. W., Alemayehu W. G., Westerhout C. M., Voors A. A., Butler J., Lam C. S. P., Ponikowski P., Emdin M., Patel M. J., Pieske B., Roessig L., Hernandez A. F., Armstrong P. W.

المساهمون: Ezekowitz, J. A., O'Connor, C. M., Troughton, R. W., Alemayehu, W. G., Westerhout, C. M., Voors, A. A., Butler, J., Lam, C. S. P., Ponikowski, P., Emdin, M., Patel, M. J., Pieske, B., Roessig, L., Hernandez, A. F., Armstrong, P. W.

مصطلحات موضوعية: clinical outcome, heart failure, heart failure with reduced ejection fraction, natriuretic peptide

الوصف: Objectives: The purpose of this study was to examine the treatment effect of vericiguat in relation to N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at randomization. Background: Vericiguat compared with placebo reduced the primary outcome of cardiovascular death (CVD) or heart failure hospitalization (HFH) in patients with HF with reduced ejection fraction (HFrEF) in the VICTORIA (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction) trial. Because an interaction existed between treatment and the primary outcome according to pre-specified quartiles of NT-proBNP at randomization, we examined this further. Methods: This study evaluated the NT-proBNP relationship with the primary outcome in 4,805 of 5,050 patients as a risk-adjusted, log-transformed continuous variable. Hazard ratios (HRs) and 95% confidence intervals (CIs) are presented. Results: Median NT-proBNP was 2,816 pg/ml (25th to 75th percentile: 1,556 to 5,314 pg/ml). The study treatment effect varied across the spectrum of NT-proBNP at randomization (with log2 transformation, p for interaction = 0.002). A significant association between treatment effects existed in patients with levels <4,000 pg/ml and remained evident up to 8,000 pg/ml. A 23% relative risk reduction occurred in the primary endpoint with NT-proBNP ≤4,000 pg/ml (HR: 0.77; 95% CI: 0.68 to 0.88). For NT-proBNP values ≤4,000 pg/ml (n = 3,100), the HR was 0.78 (95% CI: 0.67 to 0.90) for HFH and 0.75 (95% CI: 0.60 to 0.94) for CVD. For NT-proBNP ≤8,000 pg/ml (n = 4,133), the HR was 0.85 (95% CI: 0.76 to 0.95) for the primary outcome, 0.84 (95% CI: 0.75 to 0.95) for HFH, and 0.84 (95% CI: 0.71 to 0.99) for CVD. For NT-proBNP >8,000 pg/ml (n = 672), the HR was 1.16 (95% CI: 0.94 to 1.41) for the primary outcome. Conclusions: A reduction in the primary composite endpoint and its CVD and HFH components was observed in patients on vericiguat compared with subjects on placebo with NT-proBNP levels up to 8,000 pg/ml. This provided new insight ...

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000583342100007; volume:8; issue:11; firstpage:931; lastpage:939; numberofpages:9; journal:JACC. HEART FAILURE; http://hdl.handle.net/11382/537510Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85092894816

الإتاحة: https://doi.org/10.1016/j.jchf.2020.08.008Test
http://hdl.handle.net/11382/537510Test

المؤلفون: Ezekowitz, J. A., O'Connor, C. M., Troughton, R. W., Alemayehu, W. G., Westerhout, C. M., Voors, A. A., Butler, J., Lam, C. S. P., Ponikowski, P., Emdin, M., Patel, M. J., Pieske, B., Roessig, L., Hernandez, A. F., Armstrong, P. W.

مصطلحات موضوعية: natriuretic peptide, heart failure, heart failure with reduced ejection fraction, clinical outcomes

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______3729::261eb3549518286d18c395c7557e0e2dTest
http://hdl.handle.net/11382/537510Test

المؤلفون: Willemze, A., van der Woude, D., Alemayehu, W. G., Levarht, E. W. N., Stoeken-Rijsbergen, G., Verduyn, W., de Vries, R. R. P., Houwing, J., Huizinga, T. W. J., Trouw, L. A., Toes, R. E. M.

المصدر: Annals of the Rheumatic Diseases ; volume 70, issue Suppl 2, page A1-A1 ; ISSN 0003-4967

مصطلحات موضوعية: General Biochemistry, Genetics and Molecular Biology, Immunology, Immunology and Allergy, Rheumatology

الإتاحة: https://doi.org/10.1136/ard.2010.149096.1Test

المؤلفون: van der Woude, D, Alemayehu, W G, Daha, N A, Verduyn, W, de Vries, R R P, Houwing-Duistermaat, J J, Huizinga, T W J, Toes, R E M

مصطلحات موضوعية: Supplement

وصف الملف: text/html

العلاقة: http://ard.bmj.com/cgi/content/short/69/Suppl_2/A7-cTest; http://dx.doi.org/10.1136/ard.2010.129577rTest

الإتاحة: https://doi.org/10.1136/ard.2010.129577rTest
http://ard.bmj.com/cgi/content/short/69/Suppl_2/A7-cTest

المؤلفون: van Gelder, M, van Oers, M H, Alemayehu, W G, Abrahamse-Testroote, M C J, Cornelissen, J J, Chamuleau, M E, Zachée, P, Hoogendoorn, M, Nijland, M, Petersen, E J, Beeker, A, Timmers, G-J, Verdonck, L, Westerman, M, de Weerdt, O, Kater, A P

المصدر: Bone Marrow Transplantation; June 2016, Vol. 51 Issue: 6 p799-806, 8p

مستخلص: Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) <1 year after fludarabine or <2 years after fludarabine-based immunochemotherapy or R/R with del(17p). Twenty-nine patients received ⩾3 cycles of R-DHAP and sixteen <3 cycles (4 because of disease progression, 8 for toxicity and 4 toxic deaths). Overall rate of response to R-DHAP was 58%, 31 (67%) proceeded to alloSCT after conditioning with fludarabine and 2 Gy TBI. Twenty (65%) remained free from progression at 2 years after alloSCT, including 17 without minimal residual disease. Intention-to-treat 2-year PFS and overall survival of the 46 patients were 42 and 51% (35.5 months median follow-up); del(17p) or fludarabine refractoriness had no impact. R-DHAP followed by alloSCT is a reasonable treatment to be considered for high-risk CLL patients without access or resistance to targeted therapies.